All In Biotech

Drug Trial Radar · NCT01010633

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Jan 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

406

Actual

Start

Nov 2009

Primary completion

Jun 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Nov 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Conditions

  • Inflammation
  • Pain

Interventions

  • Vehicle of Loteprednol EtabonateDrug

    1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.

  • Loteprednol EtabonateDrug

    1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resolution of Anterior Chamber Cells (ACC).Time frame: Visit 5 (Postoperative day 8)
  2. Grade 0 PainTime frame: Visit 5 (Postoperative Day 8)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb, Inc.

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.